SANTA BARBARA, Calif., Feb. 28, 2017 -- Sientra, Inc. (NASDAQ:SIEN), a medical aesthetics company ("Sientra" or the "Company"), announced today that the Company will release its fourth quarter and full year 2016 financial results on Tuesday, March 14, 2017 after market close.
Sientra will hold a conference call on Tuesday, March 14, 2017 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. A press release disclosing the Company's financial results will be distributed at approximately 1:00 p.m. PT/4:00 p.m. ET that same day.
The dial-in numbers are (844) 464-3933 for domestic callers and (765) 507-2612 for international callers. The conference ID is 77604092. A live webcast of the conference call will be available on the Investor Relations section of the Company's website at www.sientra.com.
A replay of the call will be available starting on March 14, 2017 at 4:30 p.m. PT/7:30 p.m. ET, through March 15, 2017 at 8:59 p.m. PT/11:59 p.m. ET. To access the replay, dial (855) 859-2056 for domestic callers and (404) 537-3406 for international callers, and use the replay conference ID 77604092. The webcast will be available on the Investor Relations section of the Company’s website for 30 days following the completion of the call.
About Sientra
Headquartered in Santa Barbara, California, Sientra is a medical aesthetics company committed to making a difference in patients’ lives by enhancing their body image, growing their self-esteem and restoring their confidence. The Company was founded to provide greater choice to board-certified plastic surgeons and patients in need of medical aesthetics products. The Company has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company sells its breast implants and breast tissue expanders exclusively to board-certified and board-admissible plastic surgeons and tailors its customer service offerings to their specific needs. The Company also offers a range of other aesthetic and specialty products including bioCorneum®, the professional choice in scar management.
Investor Contacts: The Ruth Group Nick Laudico / Brian Johnston (646) 536-7030 / (646) 536-7028 [email protected]


L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 



